Jiangxi Bio Ends Stabilization; Over-Allotment Option Lapses with No Additional H-Share Issuance

Bulletin Express07-26

Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that the 30-day post-listing stabilization period for its Global Offering concluded on 25 July 2026 under section 9(2) of Hong Kong’s Securities and Futures (Price Stabilizing) Rules.

During the stabilization window, China International Capital Corporation Hong Kong Securities Limited, acting as Stabilizing Manager:

• Executed over-allocations totaling 5.44 million H shares in the International Offering, equal to 15.0 % of the initial offer size.

• Conducted market purchases of the same 5.44 million H shares at prices ranging from HK $7.40 to HK $10.46 per share (excluding standard fees and levies). The final repurchase was completed on 30 June 2026 at HK $9.78 per share.

The Overall Coordinators did not exercise the Over-allotment Option, which therefore lapsed on 25 July 2026. Consequently, no additional H shares will be issued.

Following these actions, Jiangxi Bio confirmed that its shareholding structure continues to meet the public-float requirement stipulated in Listing Rule 19A.13A(1).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137493915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-26 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137493915","market":"hk","top_or_hot":-1,"title":"Jiangxi Bio Ends Stabilization; Over-Allotment Option Lapses with No Additional H-Share Issuance","media":"Bulletin Express","content":"<p>Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that the 30-day post-listing stabilization period for its Global Offering concluded on 25 July 2026 under section 9(2) of Hong Kong’s Securities and Futures (Price Stabilizing) Rules.</p>\n<p>During the stabilization window, China International Capital Corporation Hong Kong Securities Limited, acting as Stabilizing Manager:</p>\n<p>• Executed over-allocations totaling 5.44 million H shares in the International Offering, equal to 15.0 % of the initial offer size.</p>\n<p>• Conducted market purchases of the same 5.44 million H shares at prices ranging from HK $7.40 to HK $10.46 per share (excluding standard fees and levies). The final repurchase was completed on 30 June 2026 at HK $9.78 per share.</p>\n<p>The Overall Coordinators did not exercise the Over-allotment Option, which therefore lapsed on 25 July 2026. Consequently, no additional H shares will be issued.</p>\n<p>Following these actions, Jiangxi Bio confirmed that its shareholding structure continues to meet the public-float requirement stipulated in Listing Rule 19A.13A(1).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangxi Bio Ends Stabilization; Over-Allotment Option Lapses with No Additional H-Share Issuance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangxi Bio Ends Stabilization; Over-Allotment Option Lapses with No Additional H-Share Issuance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-26 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that the 30-day post-listing stabilization period for its Global Offering concluded on 25 July 2026 under section 9(2) of Hong Kong’s Securities and Futures (Price Stabilizing) Rules.</p>\n<p>During the stabilization window, China International Capital Corporation Hong Kong Securities Limited, acting as Stabilizing Manager:</p>\n<p>• Executed over-allocations totaling 5.44 million H shares in the International Offering, equal to 15.0 % of the initial offer size.</p>\n<p>• Conducted market purchases of the same 5.44 million H shares at prices ranging from HK $7.40 to HK $10.46 per share (excluding standard fees and levies). The final repurchase was completed on 30 June 2026 at HK $9.78 per share.</p>\n<p>The Overall Coordinators did not exercise the Over-allotment Option, which therefore lapsed on 25 July 2026. Consequently, no additional H shares will be issued.</p>\n<p>Following these actions, Jiangxi Bio confirmed that its shareholding structure continues to meet the public-float requirement stipulated in Listing Rule 19A.13A(1).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06915","symbol_name":"江西生物","start_time":0,"source_url":"","article_id":"1137493915","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137493915","pubTimestamp":1785061404,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that the 30-day post-listing stabilization period for its Global Offering concluded on 25 July 2026 under section 9(2) of Hong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06915":"江西生物"},"translate_title":"江西生物结束稳定；超额配股权失效，不再增发H股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06915":1},"content_text":"Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that the 30-day post-listing stabilization period for its Global Offering concluded on 25 July 2026 under section 9(2) of Hong Kong’s Securities and Futures (Price Stabilizing) Rules.\nDuring the stabilization window, China International Capital Corporation Hong Kong Securities Limited, acting as Stabilizing Manager:\n• Executed over-allocations totaling 5.44 million H shares in the International Offering, equal to 15.0 % of the initial offer size.\n• Conducted market purchases of the same 5.44 million H shares at prices ranging from HK $7.40 to HK $10.46 per share (excluding standard fees and levies). The final repurchase was completed on 30 June 2026 at HK $9.78 per share.\nThe Overall Coordinators did not exercise the Over-allotment Option, which therefore lapsed on 25 July 2026. Consequently, no additional H shares will be issued.\nFollowing these actions, Jiangxi Bio confirmed that its shareholding structure continues to meet the public-float requirement stipulated in Listing Rule 19A.13A(1).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137493915","isCrawlerRequest":true}